Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.32 |
| ▸ | NAAA | Q02083 | 2/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16042062 | 1.00 | EPHX2 (0.35) | EPHX2OGACYP2C9CYP2J2CYP2C19 | |
| SCHEMBL21178117 | 1.00 | EPHX2 (0.35) | EPHX2OGACYP2C9CYP2J2CYP2C19 | |
| SCHEMBL30823268 | 0.86 | JAK2 (0.32) | EPHX2CYP2C9CYP2J2CYP2C19 | |
| SCHEMBL21192033 | 0.83 | OGA (0.33) | OGAHRH3CYP4F2CYP4A11NAAA | |
| SCHEMBL28739277 | 0.81 | EPHX2 (0.40) | EPHX2OGACYP2C9CYP2J2CYP2C19 | |
| SCHEMBL21192296 | 0.81 | GPR119 (0.37) | OGAHRH3CYP4F2CYP4A11NAAA | |
| SCHEMBL720580 | 0.80 | GPR119 (0.38) | OGAHRH3NAAAGPR119 | |
| SCHEMBL2333367 | 0.79 | HCRTR2 (0.43) | HRH3GPR119LMNA | |
| SCHEMBL718466 | 0.77 | CYP2D6 (0.51) | CYP2C19PTGS2LMNA | |
| SCHEMBL719101 | 0.76 | EPHX2 (0.39) | EPHX2OGACYP2C9CYP2J2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12269804-B2 | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-08 | — | — | US | disclosed |
| WO-2025049254-A1 | PYRAZOLOPYRIDINE BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-12005127-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-06-11 | — | — | US | disclosed |
| CN-111770921-B | Quinoxalinone compounds, compositions, methods and kits for improving genome editing efficiency | 沃泰克斯药物股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-111757876-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3740480-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-3740483-B1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMA (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3740483-B1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMA (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3740480-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200361877-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-19 | — | — | US | disclosed |
| US-20200361877-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-19 | — | — | US | disclosed |
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| CN-111757876-A | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| WO-2019143677-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019143678-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361877-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | XRCC6, LIG1, DCK | EPHX2 2825/4885OGA 694/4885CYP2C9 2374/4885 |
| US-12269804-B2 | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency | XRCC6, LIG1, DCK | EPHX2 2825/4885OGA 694/4885CYP2C9 2374/4885 |
| US-20200353101-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | EPHX2 3667/4885OGA 1655/4885CYP2C9 2149/4885 |
| US-12005127-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | EPHX2 3667/4885OGA 1655/4885CYP2C9 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.